Nicole Stavitzski

Dana-Farber Cancer InstituteBoston, Massachusetts - 02115 |
- CLINICAL TRIALS 1
- CONDITIONS2
- INTERVENTIONS2
- SINCE2010

Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
February 2010 - December 2014
Multiple Myeloma
Neoplasms, Plasma Cell
Bortezomib
Aurora A Kinase Inhibitor Mln8237



